Study Compares Iovera Cryoneurolysis to Radiofrequency Ablation for Chronic Low Back Pain
This clinical trial compares the iovera° system to radiofrequency ablation, a standard treatment for chronic low back pain. The results could significantly influence treatment preferences and market dynamics in pain management, impacting Pacira Pharmaceuticals' competitive positioning.
Phase III
Pain Management / Chronic Low Back Pain
Status
Active
Sponsor
Pacira Pharmaceuticals
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
This clinical trial compares the iovera° system to radiofrequency ablation, a standard treatment for chronic low back pain. The results could significantly influence treatment preferences and market dynamics in pain management, impacting Pacira Pharmaceuticals' competitive positioning.
Why it matters
This clinical trial compares the iovera° system to radiofrequency ablation, a standard treatment for chronic low back pain. The results could significantly influence treatment preferences and market dynamics in pain management, impacting Pacira Pharmaceuticals' competitive positioning.
What changed
Trial Update
Analysis
A clinical trial is underway to evaluate the efficacy of the iovera° system against radiofrequency ablation for chronic low back pain.
This clinical trial compares the iovera° system to radiofrequency ablation, a standard treatment for chronic low back pain. The results could significantly influence treatment preferences and market dynamics in pain management, impacting Pacira Pharmaceuticals' competitive positioning.
Monitor trial results and participant outcomes over the 14-month study period for potential shifts in clinical practice.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.